GlassScriptPhysician profile
Marvin E Lawrence
NPI 1699770255
$4,655.18
in general payments reported to CMS, 2019-2025
32 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $144 · 2021: $308 · 2022: $179 · 2023: $697 · 2024: $1,464 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730 · Education: $49.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,729.83 |
| Education | $49.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.78 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $399.99 | 2021-2025 | |
| Gilead Sciences, INC. | $311.40 | 2019-2025 | |
| Janssen Biotech, INC. | $305.75 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $296.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $262.12 | 2022-2025 | Dupixent |
| Genzyme Corporation | $262.09 | 2023-2025 | |
| Celgene Corporation | $236.77 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $122.67 | 2020-2022 | |
| Boston Scientific Corporation | $108.49 | 2024 | Speedband Superview Super 7 |
| Celltrion USA INC. | $101.44 | 2024-2025 | Zymfentra, Vegzelma |
| Intercept Pharmaceuticals, INC. | $99.00 | 2019-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.95 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $81.96 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $72.77 | 2021-2022 | |
| Qol Medical, LLC | $70.27 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $69.53 | 2024-2025 | Voquezna |
| Allergan, INC. | $47.39 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $46.69 | 2025 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $45.99 | 2024 | Fujifilm |
| Evoke Pharma, INC. | $42.09 | 2021-2025 | |
| Orphalan INC | $41.07 | 2025 | Cuvrior |
| Ucb, INC. | $40.10 | 2019 | |
| Braintree Laboratories, INC. | $35.59 | 2020-2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $29.38 | 2023-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $23.74 | 2024 | Ibsrela |
| Novo Nordisk INC | $22.57 | 2025 | Wegovy |
| Medtronic, INC. | $16.76 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.53 | 2024 | Givlaari |
| Aimmune Therapeutics, INC. | $15.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.